NYSEMKT: ARMPArmata Pharmaceuticals Inc Stock
$1.87-0.14 (-6.97%)
Updated Jun 13, 2025
ARMP Price
$1.87
Fair Value Price
N/A
Market Cap
$67.68M
52 Week Low
$0.90
52 Week High
$3.42
P/E
N/A
P/B
-1.26x
P/S
12.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.21M
Earnings
-$426.00k
Gross Margin
100%
Operating Margin
287.48%
Profit Margin
-10.1%
Debt to Equity
-2.62
Operating Cash Flow
-$35M
Beta
0.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ARMP Overview
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company is headquartered in Marina Del Rey, California and currently employs 30 full-time employees. The firm is focused on the discovery, development and commercialization of phage therapeutics. The firm is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The firm is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ARMP's potential to beat the market
- ARMP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ARMP
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important ARMP news, forecast changes, insider trades & much more!
ARMP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARMP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARMP's cash and short-term investments ($17.08M) cannot cover ARMP's cash burn for the next year ($66.65M), once increasing cash burn (83.73%) is accounted for
Interest Coverage Financials
ARMP's profit margin has increased (+2,121.6%) in the last year from (-2,131.7%) to (-10.1%), and is approaching profitability
Profit Margin Growth Financials
ARMP's short-term liabilities ($110.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more ARMP due diligence checks available for Premium users.
Valuation
ARMP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-108.97x
Market
31.36x
ARMP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.26x
Industry
4.66x
ARMP's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.5M
Profit Margin
0%
ARMP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ARMP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$87.3M
Liabilities
$141.0M
Debt to equity
-2.62
ARMP's short-term liabilities ($110.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARMP's long-term liabilities ($30.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARMP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ARMP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.6M
Investing
-$99.0k
Financing
$10.0M
ARMP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ARMP vs Biotech Stocks
Armata Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.